3 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Anagre Cap. - Essential Thrombocythemia | Phase 4 | Completed | Yuhan Corporation | 70 | 2017-06-05 | 2021-07-21 |
| Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) INC424 - Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) | Phase 4 | Completed | Novartis Pharmaceuticals | 48 | 2012-05-01 | 2015-03-03 |
| A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Anagrelide, Hydroxyurea - Thrombocythemia, Hemorrhagic | Phase 4 | Completed | Shire | 150 | 2006-01-13 | 2021-06-02 |
Thrombocythemia, Essential (3) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Hemorrhagic Disorders (1) · Myeloproliferative Disorders (1) · Polycythemia (1) · Primary Myelofibrosis (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Bone Marrow Diseases (2) · Hemorrhagic Disorders (2) · Myeloproliferative Disorders (2)
Hydroxyurea (1) · anagrelide (1) · ruxolitinib (1)
Novartis Pharmaceuticals (1) · Shire (1) · Yuhan Corporation (1)
Bulgaria (1) · France (1) · Hungary (1) · Poland (1) · Portugal (1) · Serbia (1) · South Korea (1) · United Kingdom (1)
2004 (1)